Gitnux/Report 2026

Clinical Trials Industry Statistics

In 2019, the FDA issued 4,173 warning letters—what that means for compliance and participant safety in clinical trials today.
261Statistics
79Sources
12Sections
1Visuals
41mRead
November 11, 2026Updated
Clinical Trials Industry Statistics
Aisha OkonkwoWritten by Aisha Okonkwo·Edited by Min-ji Park·Fact-checked by Rebecca Hargrove
Published ·Updated
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The clinical trials industry at a glance

The global clinical trials market was estimated at $89.0 billion in 2025 and is forecast to reach $158.4 billion by 2033, as sponsors expand oncology, rare-disease, decentralized and technology-enabled studies.

$89.0B[25]
Global market size, 2025
7.7%[25]
Forecast CAGR, 2026–2033
50.7%[25]
North America share, 2025
15,106[72]
Trials in WHO registry, July 2025
Market size
Grand View Research estimated the global clinical trials market at $89.0 billion in 2025 and $94.0 billion in 2026. A separate estimate from Global Market Insights put the 2025 market at $66.3 billion, reflecting differences in market definition and coverage.[25][73]
Forecast & CAGR
Grand View Research forecasts the market to reach $158.4 billion by 2033 at a 7.7% CAGR from 2026 to 2033. Global Market Insights projects $144.4 billion by 2035 at an 8.3% CAGR from 2026 to 2035.[25][73]
Market share & regions
North America held 50.7% of the global market in 2025 according to Grand View Research. For active Phase III trial sites, McKinsey reported that Asia-Pacific’s share rose from 13% in 2008 to 25% in 2023, while North America declined from 41% to 32% and Europe from 38% to 34%.[25][51]
Segmentation
The market is commonly segmented by development phase—Phase I, Phase II, Phase III and Phase IV—as well as study design, indication, service, sponsor and region. Grand View Research also identifies oncology, central nervous system disorders, cardiology, infectious disease, metabolic disorders and renal/nephrology among the principal application segments.[25]
Key players & concentration
The industry remains fragmented across pharmaceutical sponsors, biotechnology companies, academic institutions, site networks and CROs rather than being controlled by a single provider. Worldwide Clinical Trials said its February 2026 acquisition of Catalyst Clinical Research created an organization with approximately 4,400 employees across more than 70 countries, illustrating the scale of leading CRO platforms.[56]
Pricing
Clinical-trial pricing varies substantially by disease, phase, geography, protocol complexity and investigational product. A 2025 systematic review of 1,378 U.S. federally sponsored cancer trials found median trial-level drug costs of $7.6 million; median costs were $56.3 million for Phase III trials and $15.1 million for trials combining immunotherapy and targeted therapy.[46]
Trends, drivers & challenges
Growth is being supported by rising chronic and rare-disease prevalence, biotechnology innovation, precision medicine, higher biopharmaceutical R&D spending and decentralized or virtual trial models. Delivery challenges include patient recruitment, site start-up delays, workforce shortages and geographic concentration; ABPI reported that only 27% of UK sites opened within the measured start-up period and 41% opened to recruitment during March 2024–February 2025.[25][74]
Consumer behavior & competition
Patient participation and sponsor site selection are becoming more data-driven, with competition focused on recruitment speed, participant diversity, evidence quality and operational predictability. In 2025, China initiated 2,948 single-country industry trials, while the United States ranked first for multinational studies across Phases I, II and III, according to ABPI.[75]
M&A
M&A activity in 2025–2026 has emphasized geographic expansion, oncology, decentralized delivery, data capabilities and end-to-end CRO services. Worldwide Clinical Trials completed its acquisition of Catalyst Clinical Research in February 2026; WEP Clinical acquired Netherlands-based Siron Clinical in January 2026; and Curavit acquired Lindus Health’s CRO assets in August 2026.[56][76][77]
Regulation
Regulation is increasingly focused on transparency, participant protection, trial diversity and harmonized registration. The FDA’s 2024 draft guidance describes diversity action plans for applicable medical-product studies, including their content, submission timing and waiver process; the WHO ICTRP provides a global view of registered interventional and observational trials through June 2026.[57][78]
Latest news
The most recent industry developments identified were consolidation among CROs and site-service providers in 2026. Worldwide Clinical Trials completed the Catalyst acquisition on February 16, 2026, WEP Clinical announced the Siron acquisition on January 5, 2026, and Curavit announced the acquisition of Lindus Health’s CRO assets on August 18, 2026.[56][76][77]
report visual · Projection

U.S. FDA CDER novel drug approvals

U.S. FDA CDER novel drug approvals grew from 48 in 2019 to 50 in 2024.

48 count
Start
+0.82%
CAGR · 5y
50 count
Projected
20192024
source-verifiedfda.gov2024

03 Statistics

Technology & Innovation

AI in the clinical trials industry

  • 537 clinical trials mentioned artificial intelligence in 2024 worldwide, up from 5 trials in 2014.[1]
  • 32.5% of surveyed clinical-trial organizations planned to use AI for protocol design and optimization in 2026.[2]
  • 92% of clinical-trial survey respondents reported increasing AI investment in 2026.[2]
  • 72.9% of early AI adopters with at least 18 months of experience reported improved clinical-trial timelines in 2026.[2]
  • 82% of clinical-trial organizations had used AI in operations for 18 months or less in 2026.[2]
  • 58% of surveyed clinical-trial organizations were using AI for protocol design and optimization in 2026.[2]

Automation in the clinical trials industry

  • 68% of medtech clinical teams needed to improve site collaboration by reducing manual processes in 2025.[3]
  • 36% of sponsors and CROs rated automating repetitive tasks somewhat important when selecting eClinical solutions in 2024.[4]
  • 68% of clinical research sites prioritized automating repetitive tasks in 2024.[5]
  • 58% of sponsors and CROs rated automating repetitive tasks very important when selecting eClinical solutions in 2024.[4]
  • 32% of medtech clinical teams relied on manual processes to manage clinical-trial activities in 2025.[3]
  • 23% of sponsors and CROs rated eliminating paper documents in clinical-trial operations somewhat important in 2024.[4]

Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)

  • 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[6]
  • 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[7]
  • 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[8]
  • 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[7]
  • 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[6]

Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)

  • 55% of biopharma AI adopters reported using AI in process development in 2024.[9]
  • 70% of global biopharma respondents had adopted an R&D data platform in 2023.[10]
  • 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[10]
  • 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[11]
  • 63% of global biopharma respondents had adopted robotics and automation in 2023.[10]

Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)

  • 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[9]
  • 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[9]
  • 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[10]
  • 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[12]
  • 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[13]

Big Data in the pharmaceuticals and biotech sector (sector benchmark)

  • 43% of small and midsize pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[8]
  • 68% of pharmaceutical companies surveyed planned to use advanced analytics in 2024.[14]
  • 48% of pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[8]

04 Statistics

Data & Analytics

Business intelligence in the clinical trials industry

  • 22% of nearly 80 pharmaceutical companies had partially implemented AI/ML solutions for real-world-insights generation by late 2024.[15]
  • 33% of survey respondents considered AI-driven data-discrepancy detection a critical platform-selection criterion.[16]
  • 11% of nearly 80 pharmaceutical companies had fully implemented AI/ML solutions for real-world-insights generation by late 2024.[15]
  • 56% of 36 documented AI/ML clinical-trial use cases supported trial conduct.[15]
  • 11% of 36 documented AI/ML clinical-trial use cases supported regulatory submissions.[15]
  • 10 sponsor interviews formed the qualitative phase of IQVIA/Frost & Sullivan’s clinical-data analytics study.[16]

Data analytics in the clinical trials industry

  • 33% of respondents considered AI-driven discrepancy detection critical when selecting a clinical-data analytics platform.[16]
  • 38% of sponsors surveyed by IQVIA/Frost & Sullivan cited data harmonization as a clinical-trial data-management challenge.[16]
  • 26% of sponsors surveyed by IQVIA/Frost & Sullivan cited consolidation of multiple clinical-data sources and formats as a challenge.[16]
  • 57% of respondents identified manual clinical-data oversight processes as a critical issue in the IQVIA/Frost & Sullivan survey.[16]
  • $3.3 million–$4.4 million was the average reported investment to implement AI/ML solutions supporting clinical-trial conduct.[15]
  • 12–16 hours was the reported AI-assisted clinical-data-cleaning time in the same 2025 comparison table.[17]

Data Quality in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[18]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[3]
  • Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[3]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[3]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[3]

Data Governance in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[19]
  • Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[20]
  • Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[19]
  • Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[19]
  • Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[18]

KPIs in the clinical trials industry

  • 85% of trials in the PACT Consortium’s year-one dataset used electronic clinical-outcome assessments as a decentralized-trial solution.[21]
  • About 50% of trials in the PACT Consortium’s year-one dataset used patient portals for decentralized data collection or engagement.[21]
  • -0.57 was the reported correlation between screen-failure rate and enrollment duration in a Tufts analysis of decentralized clinical trials.[22]
  • 20% or fewer of trials in the PACT Consortium’s year-one dataset had reached database lock or primary completion.[21]
  • 50%–90% was the completion range for most variables collected in the PACT Consortium’s year-one dataset, excluding budget and cost data.[21]
  • 4 decentralized-trial solutions per clinical trial was the average reported by participating companies in the PACT Consortium’s first year.[21]

05 Statistics

Strategy & Growth

Growth in the clinical trials industry

  • Industry-sponsored oncology trials represented 39% of global trial share in 2024 among China-headquartered companies.[23]
  • The number of registered decentralized clinical trials increased to 1,370 across the period from 2000 through 2023.[24]
  • The global clinical-trials market was estimated at $89.0 billion in 2025.[25]
  • The global clinical-trials market is projected to reach $94.0 billion in 2026.[25]
  • Industry-sponsored infectious-disease trials represented 33% of global trial share in 2024 among China-headquartered companies.[23]
  • The global clinical-trials market is projected to reach $158.4 billion by 2033.[25]

Differentiation in the clinical trials industry

  • 50% of active global Alzheimer’s disease trial sites were outside the United States, demonstrating a differentiated international delivery footprint for global trial programs.[26]
  • 38 of the 40 countries with the highest oncology clinical-trial density in 2024 were high-income countries.[27]
  • China-headquartered companies accounted for 30% of global industry-sponsored clinical-trial starts in 2024, highlighting a distinct geographic competitive position.[23]

Mergers and acquisitions in the clinical trials industry

  • Clinical-trials acquisition volume reached 12 announced deals in 2019.[28]
  • Clinical-trials acquisitions represented 26% of 58 life-sciences R&D deals announced by September 12, 2025.[28]
  • Clinical-trials acquisition volume reached 14 announced deals in 2020.[28]
  • Clinical-trials acquisition volume reached 43 announced deals in 2023.[28]
  • The acquisition of Avantor’s clinical-services business was valued at $650 million in 2024.[28]
  • Clinical-trials acquisition volume reached 30 announced deals in 2022.[28]

Strategic partnerships in the clinical trials industry

  • Three U.S. academic research centers coordinated 44 multicenter clinical studies initiated between 2020 and 2022.[24]
  • The 44 studies coordinated by the three U.S. academic centers involved recruitment and enrollment across the United States.[24]
  • Parexel established a collaboration with Palantir in 2024 to apply artificial intelligence to clinical-trial data-management solutions.[29]
  • The academic-center studies coordinated sites ranging from one to 100 locations per study between 2020 and 2022.[24]
  • Moffitt Cancer Center and CMIC Group announced a strategic partnership in September 2024 to accelerate global cancer clinical trials.[30]

06 Statistics

People & Workforce

Hiring in the clinical trials industry

  • 13% of research-site respondents in the 2025 workforce survey were site directors, managers or equivalent roles.[31]
  • 23% of research-site respondents in the 2025 workforce survey were research managers or directors.[31]
  • 19% of clinical research workforce respondents said hiring and retention had improved compared with five to 10 years earlier in 2025.[31]
  • 46% of respondents to the 2025 clinical research workforce survey represented research sites.[31]
  • 30% of research-site respondents in the 2025 workforce survey were clinical research coordinators.[31]

Employee retention in the clinical trials industry

  • 52% of clinical research site survey respondents said staffing and retention were worse than five to 10 years earlier in 2025.[31]
  • 77% of clinical research professionals expressed confidence that clinical research would continue to be a fulfilling career in 2025.[31]
  • 70% of clinical research professionals expected to remain in the field for the next five to 10 years in 2025.[31]
  • 28% of clinical research workforce survey respondents said hiring and retaining staff were neither better nor worse than five to 10 years earlier.[31]
  • 58% of clinical research workforce survey respondents had worked in clinical trials for six years or more in 2025.[31]

Remote Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[32]
  • Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[32]
  • Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[33]
  • Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[34]

Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[34]
  • Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[35]
  • Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[36]
  • Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[37]

Upskilling in the clinical trials industry

  • 58% of clinical research workforce survey respondents held at least one clinical research certification in 2025.[31]
  • Only 44% of site respondents said sponsor staff had sufficient training, skills and experience to run trials successfully in the 2025 workforce survey.[31]
  • 90% of clinical research professionals reported high confidence in understanding their responsibilities in 2025.[31]
  • New clinical research hires were increasingly being placed into entry-level roles supported by training and upskilling programs in 2024.[31]
  • 44% of research-site respondents said sponsor staff had the training, skills and experience needed to run trials successfully in 2025.[31]

Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)

  • Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[38]
  • At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[39]
  • Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[38]
  • Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[38]

DEI in the clinical trials industry

  • 3,462 clinical research professionals representing approximately 3,300 investigative sites participated in the 2021 global diversity survey.[24]
  • 56% of respondents in an ACRP racial and ethnic disparities survey had previously worked on clinical-study staff in 2022.[31]
  • 64% of global investigative site personnel were White in a 2021 survey of clinical research professionals.[24]

07 Statistics

Customer & Sales

Customer experience in the clinical trials industry

  • 74% of clinical-trial sites rated protocol design, study-team communication, and monitor professionalism, knowledge, and training as very important in 2025.[40]
  • 67% was the overall clinical-trial site satisfaction score across sponsors and attributes in 2025, down from 70% in 2023.[40]
  • 87% of research-site respondents rated patient experience as very good in the clinical trials they worked on in 2025.[31]
  • 63% or less of non-site respondent groups rated patient experience as very good in the clinical trials they worked on in 2025.[31]
  • 28% was the satisfaction score among Japanese study coordinators in 2025.[40]

Customer retention in the clinical trials industry

  • 70% of CRO respondents believed they would probably still be working in clinical research in five to 10 years in 2025.[31]
  • 71% of clinical-research professionals with at least six years of experience expected to remain in the field in five to 10 years in 2025.[31]
  • 19% of clinical-research respondents believed hiring and retention of clinical-research staff had improved over the previous five to 10 years in 2025.[31]
  • 52% of clinical-research respondents said hiring and retaining clinical-research staff was worse in 2025 than five to 10 years earlier.[31]

Customer acquisition in the clinical trials industry

  • 73% of sites said a sponsor or CRO had approached them about conducting a hybrid clinical trial in the 2023 SCRS Site Landscape Survey.[41]
  • 93% of sites approached about a hybrid trial said they participated in that trial in 2023.[41]

Lead generation in the clinical trials industry

  • 83.6% of screened candidates in the 2025 cancer-trial recruitment study came through social media.[24]
  • 32% of the required sample was consented through social-media advertising over five months in a telehealth randomized trial.[42]
  • 10.8% was the screening-to-randomization rate in the 2025 cancer-trial recruitment study.[24]
  • 78.9% of 427 randomized participants in a 2025 cancer-trial recruitment study came from Facebook.[24]

08 Statistics

Marketing & Brand

Digital marketing in the clinical trials industry

  • 7% was the website conversion rate in a global polycystic-kidney-disease clinical-trial recruitment case study.[43]
  • $88.44 was the cost per enrolled Facebook participant in a breast-cancer-survivor clinical-trial recruitment study.[24]
  • 5.42% was the click-through rate for Facebook advertising in a breast-cancer-survivor clinical-trial recruitment study.[24]

Social media in the clinical trials industry

  • 9 of 17 clinical-trial studies reporting enrollment outcomes achieved or exceeded their enrollment targets in a 2020 scoping review.[24]
  • 4 of 33 clinical-trial studies reported the lowest cost per enrolled participant from social media in a 2020 scoping review.[24]
  • 3.16% was the enrollment rate among women reached through social-media recruitment in the SAFA dermatology clinical trial.[24]
  • 78.9% of randomized participants came from Facebook in a 2025 cancer-trial recruitment study.[24]
  • 209 participants were enrolled through in-house social-media recruitment in the SAFA dermatology clinical trial, at a cost of £6,649.30.[24]

Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)

  • 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[44]
  • 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[45]
  • 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[46]
  • 10% of healthcare and pharmaceutical marketers said they did not invest in creator or influencer marketing in 2026, globally.[45]
  • 50% of healthcare and pharmaceutical marketers reported dedicated and growing budgets for creator or influencer marketing in 2026, globally.[45]

09 Statistics

Operations & Execution

Process optimization in the clinical trials industry

  • 44% of companies in a Tufts patient-centricity case-study set reported improvements in clinical-study conduct cycle time after incorporating patient input into protocol design.[21]
  • 89% of Phase II protocols had at least one substantial amendment in 2021, up from 77% in 2015.[22]
  • 67% of Phase I protocols had at least one substantial amendment in 2021, up from 52% in 2015, according to a Tufts CSDD analysis.[22]
  • Phase I protocols averaged 3.1 substantial amendments in 2021, compared with 1.8 in 2015.[22]
  • 82% of Phase III protocols had at least one substantial amendment in 2021, up from 66% in 2015.[22]

Operational efficiency in the clinical trials industry

  • 56% of sites showed improved quality metrics in two historical studies that did not use statistical data monitoring.[24]
  • 83% of sites showed improved quality metrics after statistical data monitoring in an analysis of 1,111 sites across 159 clinical trials.[24]
  • 93% of PSI CRO business was repeat business in 2025.[47]
  • 97% of PSI CRO studies achieved last-patient-in milestones as planned in 2025.[47]
  • 30 weeks was the approximate time required for conventional booklet-label design, approval and shipment of clinical-trial kits to sites in a cited supply-chain analysis.[24]

Quality management in the clinical trials industry

  • 3.3% of domestic FDA clinical-investigator inspections in 1997 found major regulatory deviations and were classified as official action indicated.[48]
  • 56.3% of domestic FDA clinical-investigator inspections in 1997 found correctable objectionable conditions and were classified as voluntary action indicated.[48]
  • 81% of surveyed clinical-trial companies identified SOP management, issue and CAPA management, and inspection preparation among the responsibilities of quality-management personnel.[49]
  • 25% of cited FDA clinical-investigator inspection deficiencies involved failure to follow the protocol.[48]
  • 40.3% of domestic FDA clinical-investigator inspections in 1997 found no regulatory deviation and were classified as no action indicated.[48]

Supply chain in the clinical trials industry

  • 4–5 weeks was the minimum lead time from secondary packaging completion to clinical-trial patient kits reaching investigator sites in the DHL case study.[50]
  • 157% was the average inventory overage across one large pharmaceutical company’s clinical-trial portfolio before a DHL logistics redesign.[50]
  • 7% of packaged and labeled clinical-trial kits generated complaints in the cited McKinsey analysis.[51]
  • 50% was the median waste level for investigational-medicinal-product kits in the cited McKinsey analysis.[51]
  • 1% was the median rate of temperature-excursion deviations in the clinical-trial distribution chain in the cited McKinsey analysis.[51]

Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)

  • 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[8]
  • 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[16]
  • 40% of surveyed pharma and biotech CDMO decision-makers identified small-molecule API as the most outsourced product in July 2024.[52]
  • 12% of total API volume used in the United States was produced domestically in 2024, with most supply coming from India and the European Union.[53]
  • 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[8]

10 Statistics

Finance & Pricing

Pricing strategy in the clinical trials industry

  • $23,737 was the mean direct cost per day for Phase II clinical trials in Tufts CSDD’s analysis.[22]
  • $40,000 was the approximate mean direct cost per day for Phase II and Phase III clinical trials in Tufts CSDD’s analysis of 447 protocols, expressed in 2023 U.S. dollars.[22]
  • $55,716 was the mean direct cost per day for Phase III clinical trials in Tufts CSDD’s analysis.[22]
  • $14,091 was the mean direct cost per day for Phase IV clinical trials in Tufts CSDD’s analysis.[22]
  • $7,829 was the mean direct cost per day for Phase I clinical trials in Tufts CSDD’s analysis.[22]

Cost reduction in the clinical trials industry

  • 15% was the average overall-trial-cost saving from sample-size re-estimation in a Tufts case-study summary.[21]
  • More than $100 million in annual savings was estimated for a pharmaceutical company spending $10 billion annually on R&D if clinical-supply waste improved to best-in-class performance.[51]
  • $4 million was reportedly saved on a Phase III trial by stopping the trial one year early for efficacy in a Tufts case study.[21]
  • 20% was the average sample-size reduction associated with sample-size re-estimation in the cited Tufts case-study summary.[21]
  • 60% was the reported clinical-trial cost reduction associated with open-design or crowdsourcing approaches in a Tufts patient-centricity case-study summary.[21]

Profitability in the clinical trials industry

  • 5.6% was Charles River Laboratories’ consolidated operating-income margin in fiscal 2024.[54]
  • $227.3 million was Charles River Laboratories’ operating income in fiscal 2024.[54]
  • $2.0 billion was Charles River Laboratories’ DSA backlog at December 28, 2024.[54]
  • $4.05 billion was Charles River Laboratories’ total revenue in fiscal 2024.[54]
  • 13.8% was Charles River Laboratories’ RMS operating-income margin in fiscal 2024.[54]

Financial planning in the clinical trials industry

  • 1.9% was the year-over-year decrease in Charles River Laboratories’ total revenue from fiscal 2023 to fiscal 2024.[54]
  • $35,000 was the estimated direct cost per clinical-trial day from a Medidata analysis based on data from the 1990s, as reported by Tufts CSDD.[22]
  • $2.5 billion was Charles River Laboratories’ DSA backlog at December 30, 2023.[54]
  • 447 clinical-trial protocols were included in Tufts CSDD’s analysis of direct daily trial costs.[22]
  • $80,000–$100,000 was the reported annual decline in average prescription-drug and biologic sales per day as product launch year increased in Tufts CSDD’s analysis.[22]

11 Statistics

Product & Service

Product development in the clinical trials industry

  • 20.3% of EU/EEA clinical trials authorized during 2022–2025 investigated rare diseases, up from 17.1% during 2013–2019.[27]
  • 10,503 Phase I–III clinical trials were initiated globally in 2024, up 5.5% from 2023.[55]
  • 3.6% was the increase in industry-sponsored clinical-trial starts globally in 2024.[55]
  • 26.7% lower median cost per patient-month was reported for the 20 largest clinical-development firms than for other US-traded drug developers in 2019.[27]
  • 20 firms accounted for 80.8% of clinical-development activity among 268 US-traded drug developers in 2019, measured by patient-months.[27]

Product lifecycle in the clinical trials industry

  • 57.2 days was the mean Phase III study-closeout period during 2016–2021.[22]
  • 7% was the increase in mean Phase III clinical-trial duration between 2011–2015 and 2016–2021.[22]
  • 1,062.7 days was the mean Phase III patient-enrollment period during 2016–2021.[22]
  • 45 months was the average duration from protocol approval to database lock for Phase III trials during 2016–2021.[22]
  • 11% was the increase in mean Phase II clinical-trial duration between 2011–2015 and 2016–2021.[22]

After-sales in the clinical trials industry

  • 76% of sponsors rated midsize-CRO study-reporting services satisfactory in the 2024 worldwide benchmarking study.[56]
  • 52% of surveyed clinical-trial participants wanted reminders and calendar tools in 2019.[16]
  • 78% of surveyed clinical-trial participants wanted access to study statistics in 2019.[16]
  • 67% of sponsors rated large-CRO project-management services satisfactory in the 2024 worldwide benchmarking study.[56]
  • 89% of surveyed clinical-trial participants wanted access to their own trial data from sponsors or research providers in 2019.[16]

Value proposition in the clinical trials industry

  • 57% of sponsors surveyed by IQVIA/Frost & Sullivan identified automation of manual clinical-data oversight processes as a critical issue.[16]
  • 26% of sponsors surveyed by IQVIA/Frost & Sullivan cited consolidation of multiple data sources and formats as a key challenge.[16]
  • 33% of IQVIA/Frost & Sullivan survey respondents identified automated oversight processes as a critical feature of clinical-data analytics platforms.[16]
  • 15 percentage points was the reported satisfaction advantage of midsize CROs over large CROs for project-management expertise.[56]
  • 38% of sponsors surveyed by IQVIA/Frost & Sullivan cited data harmonization as a key clinical-trial data-management challenge.[16]

12 Statistics

Sustainability & Ethics

Ethics in the clinical trials industry

  • 43% of 20,692 U.S. clinical trials reported any race or ethnicity enrollment data, covering approximately 2.09 million participants.[24]
  • 54.6% of clinical studies reported both race and ethnicity data in 2024, up from 7.4% in 2013, based on ClinicalTrials.gov records.[24]
  • 79% was the median participation rate for White individuals in clinical trials supporting FDA drug and biologic approvals between 2015 and 2021.[24]
  • 63% was the average female participation in trials supporting 40 novel drugs approved for non-sex-specific conditions.[57]
  • 16% of participants in 258 Amgen-sponsored U.S. trials identified as Hispanic or Latino.[24]

Carbon footprint in the clinical trials industry

  • 11,070 kgCO2e came from research-meeting travel in the EMERGE randomized controlled trial.[58]
  • 2,499 kgCO2e was the mean carbon footprint per participant in phase 3 industry-sponsored clinical trials.[59]
  • 5,722 kgCO2e was the mean carbon footprint per participant in phase 2 industry-sponsored clinical trials.[59]
  • 2,498 tonnes CO2e was the estimated footprint of one pharmaceutical-sponsored late-stage clinical trial assessed in the United Kingdom.[59]
  • 8,965 kgCO2e came from document archiving in the EMERGE randomized controlled trial.[58]

14 Statistics

Globalization & Expansion

Globalization in the clinical trials industry

  • China-headquartered companies accounted for 30% of global industry-sponsored clinical-trial starts in 2024.[23]
  • 44.6% of oncology trials in lower-middle-income countries were industry-funded, compared with 5.6% in low-income countries.[27]
  • 76.4% of countries had no oncology clinical trials starting in 2024, while 38 of the 40 countries with the highest trial density were high-income countries.[27]
  • The EEA’s share of global commercial multi-country trials declined from 23% in 2018 to 19% in 2024.[70]
  • 73% of active phase 3 Alzheimer’s disease trials had globally distributed sites, compared with lower shares for phase 1 and phase 2 trials.[26]

Cultural adaptation in the clinical trials industry

  • Hispanic or Latino patients had 2.04 times the unadjusted odds of participating when the principal investigator spoke a language besides English.[26]
  • In Canadian randomized clinical trials, 72.0% of participants whose race or ethnicity was reported were White, 2.7% were Black and 0.2% were Indigenous.[27]
  • 54.6% of clinical studies registered in ClinicalTrials.gov reported both race and ethnicity in 2024, up from 7.4% in 2013.[71]
  • Participants classified as not Hispanic or Latino represented 83.2% of reported ethnicity in clinical studies in 2024.[71]
  • After adjustment for sex, race, age and insurance, Hispanic or Latino patients had 2.67 times the odds of participating when the principal investigator spoke another language.[26]

Supplier management in the clinical trials industry

  • Direct-to-patient drug delivery was used in 7.1% of decentralized clinical trials reviewed through 2023.[24]
  • 66% of clinical-development outsourcing used flexible staffing or hybrid FSP/FSO models in 2024, up from 62% in 2023.[8]
  • Remote recruitment was used in 4.1% of decentralized clinical trials reviewed through 2023.[24]
  • 40% of clinical-development outsourcing used CRO or other flexible staffing models in 2024.[8]
  • Remote or residential visits were used in 25.4% of decentralized clinical trials reviewed through 2023.[24]

Stakeholder management in the clinical trials industry

  • Among 58,163 clinical studies registered from 2009–2024, studies with only NIH funding were 1.70 times more likely to report race and ethnicity than studies with industry funding or sponsorship.[27]
  • Phase 4 studies had an odds ratio of 0.32 for reporting race and ethnicity compared with the reference phase in a 2009–2024 ClinicalTrials.gov analysis.[27]
  • 8.9% of studies in a meta-review reported engagement through a multidisciplinary team.[24]
  • 17.6% of reviewed equity-focused engagement studies addressed people living in rural, low-income or disadvantaged areas.[24]
  • 26.7% of studies in a meta-review reported translating patient engagement knowledge into practice.[24]

Distribution channels in the clinical trials industry

  • The decentralized clinical trials in the global analysis took place in 75 countries.[24]
  • Remote or residential visits appeared in 25.4% of decentralized trials reviewed through 2023.[24]
  • 1,370 decentralized clinical trials registered from 2000 to 2023 were identified in a global analysis.[24]
  • Remote data collection was the most common decentralized channel, appearing in 91.9% of trials reviewed through 2023.[24]
  • 26% of analyzed decentralized trials implemented decentralized elements to investigate the impact of an intervention.[24]
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Aisha Okonkwo. (2026, February 13). Clinical Trials Industry Statistics. Gitnux. https://gitnux.org/clinical-trials-industry-statistics
MLA
Aisha Okonkwo. "Clinical Trials Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/clinical-trials-industry-statistics.
Chicago
Aisha Okonkwo. 2026. "Clinical Trials Industry Statistics." Gitnux. https://gitnux.org/clinical-trials-industry-statistics.

Sources & references

79 sources cited across this report

  1. hai.stanford.edu
  2. medidata.com
  3. veeva.com
  4. 23578418.fs1.hubspotusercontent-na1.net
  5. florencehc.com
  6. pmlive.com
  7. ispe.org
  8. ppd.com
  9. test.benchling.com
  10. techresearchinfo.com
  11. benchling.com
  12. deloitte.com
  13. insights.indegene.com
  14. pharmamanufacturing.com
  15. milkeninstitute.org
  16. iqvia.com
  17. medicaljournals.se
  18. capgemini.com
  19. pistoiaalliance.org
  20. resources.indegene.com
  21. sites.tufts.edu
  22. csdd.tufts.edu
  23. makingpharmaindustry.it
  24. pmc.ncbi.nlm.nih.gov
  25. grandviewresearch.com
  26. pubmed.ncbi.nlm.nih.gov
  27. doi.org
  28. healthcare.levinassociates.com
  29. en.wikipedia.org
  30. moffitt.org
  31. acrpnet.org
  32. innovatebio.org
  33. jthelander.com
  34. naceweb.org
  35. massbio.org
  36. biobuzz.io
  37. assets.kpmg.com
  38. cultureamp.com
  39. amneal.com
  40. wcgclinical.com
  41. myscrs.org
  42. jmir.org
  43. parexel.subjectwell.com
  44. sermo.com
  45. brand-news.it
  46. jamanetwork.com
  47. psi-cro.com
  48. ncbi.nlm.nih.gov
  49. eymj.org
  50. dhl.com
  51. mckinsey.com
  52. glginsights.com
  53. richmondfed.org
  54. sec.gov
  55. citeline.com
  56. worldwide.com
  57. fda.gov
  58. papers.ssrn.com
  59. bmjopen.bmj.com
  60. eclincloud.com
  61. middlemarketcenter.org
  62. acrohealth.org
  63. lifesciencesny.org
  64. fortinet.com
  65. cpl.thalesgroup.com
  66. kiteworks.com
  67. etla.fi
  68. openpharma.blog
  69. insights.economistenterprise.com
  70. efpia.eu
  71. bmjopenquality.bmj.com
  72. cdn.who.int
  73. gminsights.com
  74. abpi.uksouth01.umbraco.io
  75. abpi.org.uk
  76. wepclinical.com
  77. prnewswire.com
  78. who.int
  79. axios.com